The high mutational burden observed in desmoplastic melanoma is of significance for patient response to immunotherapy: in fact, a higher overall mutational load determines the expression of more neoantigens and a greater sensitivity to anti-tumor immunotherapies compared to those based on anti-PD1/anti-PDL1 antibodies [153]. The gene discussed is CD274; the disease is neoplasm.